JP7630012B2 - Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法 - Google Patents

Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法 Download PDF

Info

Publication number
JP7630012B2
JP7630012B2 JP2023560003A JP2023560003A JP7630012B2 JP 7630012 B2 JP7630012 B2 JP 7630012B2 JP 2023560003 A JP2023560003 A JP 2023560003A JP 2023560003 A JP2023560003 A JP 2023560003A JP 7630012 B2 JP7630012 B2 JP 7630012B2
Authority
JP
Japan
Prior art keywords
antibody
pmr
week
antigen
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023560003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526414A (ja
Inventor
ジェニファー・スローン・ラザル
ヨン・リン
ワンリン・ワォン
イン・リュウ
リタ・アラウホ
ダニエル・イサマン
ケリー・フォード
ステファノ・フィオーレ
フレデリク・マラッシュ
チャド・ニーヴンス
ボランル・アキンレード
アンジェリキ・ジャンネッロウ
ジェフリー・カーティス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2024526414A publication Critical patent/JP2024526414A/ja
Priority to JP2025014698A priority Critical patent/JP2025072440A/ja
Application granted granted Critical
Publication of JP7630012B2 publication Critical patent/JP7630012B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023560003A 2022-04-06 2023-04-05 Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法 Active JP7630012B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025014698A JP2025072440A (ja) 2022-04-06 2025-01-31 Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202263327850P 2022-04-06 2022-04-06
US63/327,850 2022-04-06
US202263350761P 2022-06-09 2022-06-09
US63/350,761 2022-06-09
US202263389317P 2022-07-14 2022-07-14
US63/389,317 2022-07-14
US202263424035P 2022-11-09 2022-11-09
US63/424,035 2022-11-09
US202263424627P 2022-11-11 2022-11-11
US63/424,627 2022-11-11
US202363445331P 2023-02-14 2023-02-14
US202363445329P 2023-02-14 2023-02-14
US63/445,331 2023-02-14
US63/445,329 2023-02-14
US202363447796P 2023-02-23 2023-02-23
US63/447,796 2023-02-23
PCT/US2023/065361 WO2023196838A1 (en) 2022-04-06 2023-04-05 Compositions and methods for treating polymyalgia rheumatica by administering an il‑6r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025014698A Division JP2025072440A (ja) 2022-04-06 2025-01-31 Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2024526414A JP2024526414A (ja) 2024-07-18
JP7630012B2 true JP7630012B2 (ja) 2025-02-14

Family

ID=86424726

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023560003A Active JP7630012B2 (ja) 2022-04-06 2023-04-05 Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法
JP2025014698A Pending JP2025072440A (ja) 2022-04-06 2025-01-31 Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025014698A Pending JP2025072440A (ja) 2022-04-06 2025-01-31 Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法

Country Status (11)

Country Link
US (1) US20230399410A1 (https=)
EP (1) EP4504788A1 (https=)
JP (2) JP7630012B2 (https=)
KR (1) KR20240164816A (https=)
CN (1) CN120569404A (https=)
AU (1) AU2023250653A1 (https=)
CA (1) CA3247400A1 (https=)
IL (1) IL316091A (https=)
MX (1) MX2024012345A (https=)
TW (1) TW202405014A (https=)
WO (1) WO2023196838A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025149845A1 (en) * 2024-01-12 2025-07-17 Sanofi Biotechnology Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid
WO2025149846A1 (en) * 2024-01-12 2025-07-17 Sanofi Biotechnology Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2017106312A1 (en) * 2015-12-18 2017-06-22 Drexel University Methods of modulating levels of il-6 and pd-l1
EP3980459A1 (en) * 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ann. Rheum. Dis.，2020年，vol.79, issue Suppl.1，p.717,718(FRI0266)
Int. J. Rheum. Dis. ，2019年，vol.22, issue S3，p.204(3-145)
J. Clin. Med.，vol.10, issue 13，2948, p.1-8
Ther. Clin. Risk Manag.，2019年，vol.15，p.1073-1079

Also Published As

Publication number Publication date
MX2024012345A (es) 2024-11-08
IL316091A (en) 2024-12-01
JP2025072440A (ja) 2025-05-09
TW202405014A (zh) 2024-02-01
US20230399410A1 (en) 2023-12-14
WO2023196838A1 (en) 2023-10-12
AU2023250653A1 (en) 2024-11-21
KR20240164816A (ko) 2024-11-20
EP4504788A1 (en) 2025-02-12
JP2024526414A (ja) 2024-07-18
CA3247400A1 (en) 2023-10-12
CN120569404A (zh) 2025-08-29

Similar Documents

Publication Publication Date Title
US20260027202A1 (en) Treatment of rheumatoid arthritis with an il-6r antibody
TWI604851B (zh) Ｉｌ－１７抗體用於製備治療強直性脊椎炎之藥物之用途
EP3071230B1 (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
US20180296670A1 (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
AU2018204346A1 (en) Methods for treating atopic dermatitis by administering an IL-4R antagonist
JP2025072440A (ja) Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法
US20230127528A1 (en) Compositions and methods for treating juvenile idiopathic arthritis
JP2017528465A (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用
JP2020045351A (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
RU2822089C2 (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита
TW202547482A (zh) 已接受類固醇之具有風濕性多肌痛症之個體之治療
WO2025149846A1 (en) Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist
HK1225635B (en) Compositions for the treatment of rheumatoid arthritis and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231228

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250203

R150 Certificate of patent or registration of utility model

Ref document number: 7630012

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150